Nanovesicles released by OKT3 hybridoma express fully active antibodies

References

• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018;9:86–120.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851–5.
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321:522–5.
   PubMed Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552–4.
   PubMed Web of Science ®Google Scholar
• Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433–55.
   PubMed Web of Science ®Google Scholar
• Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 2005;23:344–8.
   PubMed Web of Science ®Google Scholar
• Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994;7:13–21.
   PubMed Web of Science ®Google Scholar
• Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994;368:856–9.
   PubMed Web of Science ®Google Scholar
• Griffiths AD, Duncan AR. Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 1998;9:102–8.
   PubMed Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, et al. scFv antibody: principles and clinical application. Clin Dev Immunol 2012;2012:980250–15.
   PubMed Web of Science ®Google Scholar
• Monnier P, Vigouroux R, Tassew N. In vivo applications of single chain Fv (variable domain) (scFv) fragments. Antibodies 2013;2:193–208.
   Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself 2010;1:314–22.
   PubMedGoogle Scholar
• De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008;8:620–6.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Deshpande M, Yang J, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PloS One 2016;11:e0159328.
   PubMed Web of Science ®Google Scholar
• Dimitrov I, Atanasova M, Patronov A, et al. A cohesive and integrated platform for immunogenicity prediction. Methods Mol Biol 2016;1404:761–70.
   PubMedGoogle Scholar
• Kizhedath A, Wilkinson S, Glassey J. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope. Arch Toxicol 2017;91:1595–612.
   PubMed Web of Science ®Google Scholar
• Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191:1209–20.
   PubMed Web of Science ®Google Scholar
• Shudo K, Kinoshita K, Imamura R, et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001;31:2504–11.
   PubMed Web of Science ®Google Scholar
• Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045–50.
   PubMed Web of Science ®Google Scholar
• Geppert TD, Lipsky PE. Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J Immunol 1987;138:1660–6.
   PubMed Web of Science ®Google Scholar
• Geppert TD, Lipsky PE. Activation of T lymphocytes by immobilized monoclonal antibodies to CD3. Regulatory influences of monoclonal antibodies to additional T cell surface determinants. J Clin Investig 1988;81:1497–505.
   PubMed Web of Science ®Google Scholar
• Thümmler K, Häntzschel N, Skapenko A, et al. Surfactant-free poly(styrene-co-glycidyl methacrylate) particles with surface-bound antibodies for activation and proliferation of human T cells. Bioconjugate Chem 2010;21:867–74.
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Ann Rev Cell Dev Biol 2014;30:255–89.
   PubMed Web of Science ®Google Scholar
• Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 2011;81:1171–82.
   PubMed Web of Science ®Google Scholar
• Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009;21:575–81.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Angelini DF, Iessi E, et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett 2017;403:318–29.
   PubMed Web of Science ®Google Scholar
• Logozzi M, Angelini DF, Giuliani A, et al. Increased plasmatic levels of PSA-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: a prospective study. Cancers 2019;11:1449.
   Web of Science ®Google Scholar
• Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161–72.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594–600.
   PubMed Web of Science ®Google Scholar
• Näslund TI, Gehrmann U, Qazi KR, et al. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol 2013;190:2712–9.
   PubMed Web of Science ®Google Scholar
• Admyre C, Grunewald J, Thyberg J, et al. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur Respir J 2003;22:578–83.
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Shen R-F, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 2004;101:13368–73.
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6:267–83.
   PubMed Web of Science ®Google Scholar
• Admyre C, Bohle B, Johansson SM, et al. B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J Allergy Clin Immunol 2007;120:1418–24.
   PubMed Web of Science ®Google Scholar
• Caby M-P, Lankar D, Vincendeau-Scherrer C, et al. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005;17:879–87.
   PubMed Web of Science ®Google Scholar
• Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PloS One 2009;4:e5219.
   PubMed Web of Science ®Google Scholar
• Properzi F, Logozzi M, Abdel-Haq H, et al. Detection of exosomal prions in blood by immunochemistry techniques. J Gen Virol 2015;96:1969–74.
   PubMed Web of Science ®Google Scholar
• Hong C-S, Funk S, Muller L, et al. Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Ves 2016;5:29289.
   PubMed Web of Science ®Google Scholar
• Capello M, Vykoukal JV, Katayama H, et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun 2019;10:254.
   PubMed Web of Science ®Google Scholar
• Familari M, Cronqvist T, Masoumi Z, Hansson SR. Placenta-derived extracellular vesicles: their cargo and possible functions. Reprod Fertil Dev 2017;29:433–47.
   PubMed Web of Science ®Google Scholar
• Iaccino E, Mimmi S, Dattilo V, et al. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Mol Cancer 2017;16:159.
   PubMed Web of Science ®Google Scholar
• Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303–16.
   PubMed Web of Science ®Google Scholar
• Huber V, Fais S, Iero M, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005;128:1796–804.
   PubMed Web of Science ®Google Scholar
• Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science (New York, N.Y.) 1979;206:347–9.
   PubMed Web of Science ®Google Scholar
• Van Wauwe JP, De Mey JR, Goossens JG. Pillars article: OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 2016;197:3431–6.
   PubMed Web of Science ®Google Scholar
• Goldstein G. Monoclonal antibody specificity: orthoclone OKT3 T-cell blocker. Nephron 1987;46:5–11.
   PubMed Web of Science ®Google Scholar
• Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569–79.
   PubMed Web of Science ®Google Scholar
• Carr B, Wright M. Nanoparticle tracking analysis; a review of applications and usage 2010–2012 amesbury. Wiltshire: NanoSight; 2013.
   Google Scholar
• Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Ves 2018;7:1535750.
   PubMed Web of Science ®Google Scholar
• Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002;360:295–305.
   PubMed Web of Science ®Google Scholar
• Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006;3:3.22.
   Google Scholar
• Posner J, Barrington P, Brier T, Datta-Mannan A, Monoclonal antibodies: past, present and future. In: Barrett JE, Page CP, Michel MC, editors. Concepts and principles of pharmacology. Vol. 260. Cham: Springer International Publishing; 2019.
   Google Scholar
• Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014;14:195–208.
   PubMed Web of Science ®Google Scholar
• Saunderson SC, Schuberth PC, Dunn AC, et al. Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. J Immunol 2008;180:8146–52.
   PubMed Web of Science ®Google Scholar
• Nolte-'t Hoen ENM, Buschow SI, Anderton SM, et al. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 2009;113:1977–81.
   PubMed Web of Science ®Google Scholar
• Muntasell A, Berger AC, Roche PA. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J 2007;26:4263–72.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493–507.
   PubMed Web of Science ®Google Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018;9:15–32.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66:7630–8.
   PubMed Web of Science ®Google Scholar
• Fernández-Sánchez E, Ducongé J, Castillo R, et al. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol 2002;54:59–64.
   PubMed Web of Science ®Google Scholar
• Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Therap 2004;310:896–904.
   PubMed Web of Science ®Google Scholar
• Lampson LA. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. mAbs 2011;3:153–60.
   PubMed Web of Science ®Google Scholar
• Loureiro JA, Gomes B, Coelho MAN, et al. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Nanomedicine 2014;9:709–22.
   PubMed Web of Science ®Google Scholar
• Han L, Liu C, Qi H, et al. Systemic delivery of monoclonal antibodies to the central nervous system for brain tumor therapy. Adv Mater 2019;31:e1805697.
   PubMed Web of Science ®Google Scholar